Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...
The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback